Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Gross Margin (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Gross Margin data on record, last reported at 51.7% in Q4 2025.

  • For Q4 2025, Gross Margin fell 3532.0% year-over-year to 51.7%; the TTM value through Oct 2025 reached 66.84%, up 1043.0%, while the annual FY2025 figure was 86.75%, 4537.0% up from the prior year.
  • Gross Margin reached 51.7% in Q4 2025 per CSBR's latest filing, up from 42.87% in the prior quarter.
  • Across five years, Gross Margin topped out at 120.25% in Q2 2025 and bottomed at 64.69% in Q2 2021.
  • Average Gross Margin over 5 years is 56.49%, with a median of 54.83% recorded in 2021.
  • Peak YoY movement for Gross Margin: plummeted -15227bps in 2021, then surged 14970bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 52.41% in 2021, then decreased by -9bps to 47.88% in 2022, then soared by 76bps to 84.49% in 2023, then increased by 3bps to 87.02% in 2024, then crashed by -41bps to 51.7% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 51.7% in Q4 2025, 42.87% in Q3 2025, and 120.25% in Q2 2025.